IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by MetLife Investment Management LLC

MetLife Investment Management LLC reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,082 shares of the medical research company’s stock after selling 3,423 shares during the period. MetLife Investment Management LLC’s holdings in IQVIA were worth $10,920,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. PGGM Investments grew its stake in IQVIA by 55.8% in the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after purchasing an additional 4,326 shares in the last quarter. Simplify Asset Management Inc. increased its holdings in shares of IQVIA by 67.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after acquiring an additional 3,894 shares during the last quarter. Raymond James & Associates raised its position in shares of IQVIA by 0.7% during the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock valued at $169,231,000 after acquiring an additional 5,417 shares in the last quarter. Versor Investments LP bought a new position in IQVIA during the third quarter worth $1,328,000. Finally, Gradient Investments LLC boosted its holdings in IQVIA by 15.6% in the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock worth $9,600,000 after purchasing an additional 6,134 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 0.1 %

Shares of IQV stock opened at $201.43 on Friday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a market cap of $36.56 billion, a PE ratio of 26.43, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51. The business’s fifty day moving average is $219.50 and its 200-day moving average is $226.40. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on IQV. Truist Financial reduced their price target on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Evercore ISI decreased their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Barclays lowered their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Morgan Stanley cut their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Finally, TD Cowen lowered their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Five analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.